Envestnet Asset Management Inc Puma Biotechnology, Inc. Transaction History

Envestnet Asset Management Inc

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 04, 2022	SELL	$2.85 - $6.58 $385,394 - $889,787	-135,226 Closed	0 $0
Q3 2021 Oct 07, 2021	BUY	$6.63 - $9.39 $12,901 - $18,272	1,946 Added 1.46%	135,226 $948,000
Q2 2021 Aug 04, 2021	BUY	$8.98 - $11.6 $49,551 - $64,008	5,518 Added 4.32%	133,280 $1.22 Million
Q1 2021 May 04, 2021	BUY	$9.38 - $13.63 $998,257 - $1.45 Million	106,424 Added 498.75%	127,762 $1.24 Million
Q4 2020 Feb 02, 2021	BUY	$7.78 - $12.13 $2,800 - $4,366	360 Added 1.72%	21,338 $219,000
Q3 2020 Oct 09, 2020	BUY	$9.5 - $11.14 $2,061 - $2,417	217 Added 1.05%	20,978 $212,000
Q2 2020 Jul 08, 2020	SELL	$7.01 - $13.24 $9,084 - $17,159	-1,296 Reduced 5.88%	20,761 $217,000
Q1 2020 Apr 23, 2020	BUY	$6.28 - $14.57 $66,687 - $154,718	10,619 Added 92.84%	22,057 $186,000
Q4 2019 Feb 11, 2020	BUY	$6.5 - $10.73 $1,423 - $2,349	219 Added 1.95%	11,438 $100,000
Q3 2019 Oct 17, 2019	BUY	$8.75 - $12.85 $98,166 - $144,164	11,219 New	11,219 $121,000
Q2 2019 Aug 02, 2019	SELL	$12.3 - $35.76 $80,392 - $233,727	-6,536 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$20.77 - $42.37 $135,752 - $276,930	6,536 New	6,536 $254,000
Q3 2018 Nov 14, 2018	SELL	$41.2 - $59.85 $7,828 - $11,371	-190 Closed	0 $0
Q2 2018 Aug 10, 2018	SELL	$48.3 - $68.25 $386 - $546	-8 Reduced 4.04%	190 $11,000
Q1 2018 May 09, 2018	BUY	$59.7 - $99.25 $3,283 - $5,458	55 Added 38.46%	198 $13,000
Q4 2017 Feb 20, 2018	BUY	$93.85 - $132.45 $4,598 - $6,490	49 Added 52.13%	143 $14,000
Q3 2017 Nov 13, 2017	BUY	$72.0 - $119.75 $6,768 - $11,256	94	94 $11,000

103

29M

60.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $137M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Envestnet Asset Management Inc with notifications on news.